382 results on '"Takehara, Kazuhiro"'
Search Results
52. A case of ependymoma arising from the peritoneum
53. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group
54. A case of uterine corpus large cell neuroendocrine carcinoma showing prominent myometrial invasion without any macroscopically clear tumor formation
55. Saturday, July 13, 202410:30 AM - 11:30 AM GPP01 Presentation Time: 10:30 AM: A Phase 3 Study of Pembrolizumab (Pembro) + Chemoradiotherapy (CCRT) for High-Risk Locally Advanced Cervical Cancer (LACC)
56. Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/ KEYNOTE ‐775
57. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study
58. Dose optimization for MORAb-202, an antibody-drug conjugate (ADC) highly selective for folate receptor-alpha (FRα), using population pharmacokinetic (PPK) and exposure-response (E-R) efficacy and safety analyses.
59. Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial.
60. Clear cell carcinoma of the endometrium
61. The usefulness of 18F-FDG-PET/CT in discriminating benign from malignant ovarian teratomas
62. How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey
63. Clear cell carcinoma of the endometrium
64. Laparoscopic Triple Segmental Bowel Resection for Endometriosis Revealed by Rectal Obstruction during Infertility Treatment
65. Study of Purse-string Skin Closure Plus Negative-pressure Wound Therapy for Stoma Closure
66. Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma
67. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
68. Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group
69. Neoadjuvant Chemotherapy of Docetaxel and Carboplatin followed by Radical Hysterectomy could be Promising Treatment in Patients with Stage Ib2 to IIb usual-type Adenocarcinoma: Updated Result of an Advance Study of SGSG-005.: YGA O 04
70. Clinical pathway to discharge 3 days after colorectal endoscopic submucosal dissection
71. Regional differences in human papillomavirus type 52 prevalence among Japanese women with cervical intraepithelial neoplasia†.
72. Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775.
73. Superior mesenteric vein thrombosis as a complication of acute appendicitis : report of a case
74. O9-1 Updated results of a phase 2 study of niraparib in heavily pretreated high-grade serous ovarian cancer patients in Japan
75. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
76. Evaluation of Colonic Perfusion for Colorectal Cancer Surgery Using Indocyanine Green Fluorescence Imaging
77. JGOG2051: The safety and efficacy of repeated high-dose luteal hormone (MPA) therapy for recurrent early-stage endometrial cancer patients
78. Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer
79. Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer
80. A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOGG1303, DOENCA trial
81. Characterization of autoantibodies to ferritin in canine serum
82. Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women.
83. A Phase II Clinical Trial of Topotecan in Japanese Patients with Relapsed Ovarian Carcinoma
84. Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer
85. Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan
86. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial
87. Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
88. Comparison of Prognostic Indicators in Patients Undergoing Palliative Surgery
89. Application of deep learning to the classification of uterine cervical squamous epithelial lesion from colposcopy images combined with HPV types
90. Changes in the Clinicopathological Demographics of Vulvar Cancer in Japan: Increasing Oldest-Old, Stage Shifting, and Decreasing Cohort-Level Survival †
91. Acantholytic squamous cell carcinoma of the uterine cervix
92. Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Müllerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group
93. Application of deep learning to the classification of uterine cervical squamous epithelial lesion from colposcopy images
94. KN100: Results from Japanese patients with advanced recurrent ovarian cancer treated with pembrolizumab monotherapy
95. A phase II, open labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine corpus cancer: KCOGG1303 study.
96. Determination of eligibility criteria for salvage hysterectomy after definitive radiotherapy/concurrent chemoradiotherapy for residual cervical disease.
97. Aggregated results of a questionnaire survey about cytology specimens conducted by a fixed-point observation
98. Uterine leiomyosarcoma well-controlled with eribulin mesylate
99. Recurrence of invasive cervical carcinoma more than 5 years after initial therapy
100. Application of deep learning to the classification of uterine cervical squamous epithelial lesion from colposcopy images combined with HPV types.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.